首页> 美国卫生研究院文献>Journal of Clinical Medicine >High CD200 Expression on T CD4+ and T CD8+ Lymphocytes as a Non-Invasive Marker of Idiopathic Pulmonary Hypertension–Preliminary Study
【2h】

High CD200 Expression on T CD4+ and T CD8+ Lymphocytes as a Non-Invasive Marker of Idiopathic Pulmonary Hypertension–Preliminary Study

机译:T CD4 +和T CD8 +淋巴细胞的高CD200表达作为特发性肺动脉高压初步研究的非侵入性标志物

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Pulmonary arterial hypertension (PAH) can develop subsequently to disorganized endothelial cell proliferation within the pulmonary arteriolar layers that provide mechanical limits to the pulmonary vascular bed. Although the actual factor triggering vascular endothelial proliferation remains unknown to date, genetic susceptibility, hypoxia, inflammation, as well as response to drugs and toxins have been proposed as possible contributors. Since inflammation contributes to vascular remodeling, the changed immune response is increasingly considered a plausible cause of this cardiovascular disease. The interaction of a membrane glycoprotein cluster of differentiation 200 (CD200) and its structurally similar receptor (CD200R) plays a crucial role in the modulation of the inflammatory response. Our previous studies have shown that the overexpression of the other negative co-stimulatory molecule (programmed death cell-PD-1) and its ligand-1 (PD-L1) is closely related to iPAH and the presence of Epstein-Barr virus (EBV) reactivation markers. Therefore, we considered it necessary to analyze the different types of PAH in terms of CD200 and CD200R expression and to correlate CD200/CD200R pathway expression with important clinical and laboratory parameters. The CD200/C200R-signaling pathway has not been subject to much research. We included 70 treatment-naïve, newly diagnosed patients with PAH in our study. They were further divided into subsets according to the pulmonary hypertension classification: chronic thromboembolic pulmonary hypertension (CTEPH) subset, pulmonary arterial hypertension associated with congenital heart disease (CHD-PAH), pulmonary arterial hypertension associated with connective tissue disease (CTD-PAH), and idiopathic pulmonary arterial hypertension (iPAH). The control group consisted of 20 healthy volunteers matched for sex and age. The highest percentages of T CD200+CD4+ and T CD200+CD8+ lymphocytes were observed in the group of patients with iPAH and this finding was associated with the presence of EBV DNA in the peripheral blood. Our assessment of the peripheral blood lymphocytes expression of CD200 and CD200R indicates that these molecules act as negative co-stimulators in the induction and persistence of PAH-associated inflammation, especially that of iPAH. Similar results imply that the dysregulation of the CD200/CD200R axis may be involved in the pathogenesis of several immune diseases. Our work suggests that CD200 and CD200R expression may serve to distinguish between PAH cases. Thus, CD200 and CD200R might be useful as markers in managing PAH and should be further investigated.
机译:肺动脉高压(PAH)可以随后在肺动脉瘤层内进行混乱的内皮细胞增殖,为肺血管床提供机械限制。虽然触发血管内皮增殖的实际因素仍然是迄今为止,遗传易感性,缺氧,炎症以及对药物和毒素的反应也是可能的贡献者。由于炎症有助于血管重塑,因此改变的免疫应答越来越多地被认为是这种心血管疾病的可符号原因。膜糖蛋白的分化200(CD200)和其结构相似的受体(CD200R)的相互作用在调节炎症反应的调节中起着至关重要的作用。我们以前的研究表明,其他负协刺激分子(编程死亡细胞-PD-1)及其配体-1(PD-L1)的过表达与IPAH和Epstein-Barr病毒的存在密切相关(EBV )重新激活标记。因此,我们认为在CD200和CD200R表达方面需要分析不同类型的PAH,并与重要的临床和实验室参数相关联CD200 / CD200R途径表达。 CD200 / C200R信号通路途径并未受到大量研究。我们在我们的研究中包括70种治疗 - 幼稚,新诊断的PAH患者。根据肺动脉高压分类,它们被进一步分为亚群:慢性血栓栓塞肺动脉高血压(CTEPH)子集,与先天性心脏病(CHD-PAH)相关的肺动脉高血压,与结缔组织疾病相关的肺动脉高血压(CTD-PAH),和特发性肺动脉高压(IPAH)。对照组由20名健康志愿者组成,符合性别和年龄。在IPAH患者组中观察到T CD200 + CD4 +和T CD200 + CD8 +淋巴细胞的最高百分比。该发现与外周血中的EBV DNA存在有关。我们对CD200和CD200R的外周血淋巴细胞表达的评估表明,这些分子在诱导和持续存在PAH相关炎症的诱导和持续存在下,尤其是IPAH的表达。类似的结果意味着CD200 / CD200R轴的失调可能涉及几种免疫疾病的发病机制。我们的作品表明CD200和CD200R表达可用于区分PAH病例。因此,CD200和CD200R可用作管理PAH的标记,并且应该进一步调查。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号